Becton, Dickinson and Company (NYSE:BDX) Issues FY24 Earnings Guidance

Becton, Dickinson and Company (NYSE:BDX) updated its FY24 earnings guidance on Thursday. The company provided EPS guidance of $12.95-13.15 for the period, compared to the consensus EPS estimate of $12.95. The company issued revenue guidance of ~$20.1-20.3 billion, compared to the consensus revenue estimate of $20.30 billion.

Wall Street Analysts Forecast Growth

Several research analysts have commented on BDX shares. Barclays lifted their target price on Becton, Dickinson and Company from $301.00 to $305.00 and gave the stock an overweight rating in a report on Monday, February 5th. Raymond James lifted their target price on Becton, Dickinson and Company from $269.00 to $275.00 and gave the stock an outperform rating in a report on Wednesday, January 3rd. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of Moderate Buy and a consensus price target of $280.00.

Becton, Dickinson and Company Trading Up 2.7 %

Shares of NYSE:BDX traded up $6.41 during midday trading on Thursday, reaching $240.13. The company’s stock had a trading volume of 910,753 shares, compared to its average volume of 1,372,935. The firm has a market capitalization of $69.37 billion, a price-to-earnings ratio of 55.41, a PEG ratio of 1.94 and a beta of 0.45. The company has a debt-to-equity ratio of 0.56, a quick ratio of 0.64 and a current ratio of 1.08. The firm has a 50 day moving average price of $238.75 and a two-hundred day moving average price of $240.71. Becton, Dickinson and Company has a fifty-two week low of $229.40 and a fifty-two week high of $287.32.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings data on Thursday, May 2nd. The medical instruments supplier reported $3.17 EPS for the quarter, topping analysts’ consensus estimates of $2.97 by $0.20. The firm had revenue of $5.05 billion during the quarter, compared to analyst estimates of $5.04 billion. Becton, Dickinson and Company had a return on equity of 13.57% and a net margin of 6.44%. The company’s revenue for the quarter was up 4.6% on a year-over-year basis. During the same period in the previous year, the company posted $2.86 EPS. As a group, analysts forecast that Becton, Dickinson and Company will post 12.94 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 28th. Shareholders of record on Monday, June 10th will be issued a dividend of $0.95 per share. This represents a $3.80 dividend on an annualized basis and a yield of 1.58%. The ex-dividend date is Monday, June 10th. Becton, Dickinson and Company’s dividend payout ratio is currently 90.05%.

Insider Activity

In other news, SVP Thomas J. Spoerel sold 282 shares of the company’s stock in a transaction that occurred on Thursday, March 14th. The stock was sold at an average price of $238.29, for a total value of $67,197.78. Following the completion of the transaction, the senior vice president now directly owns 2,276 shares of the company’s stock, valued at $542,348.04. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In related news, SVP Thomas J. Spoerel sold 282 shares of the company’s stock in a transaction that occurred on Thursday, March 14th. The stock was sold at an average price of $238.29, for a total value of $67,197.78. Following the transaction, the senior vice president now owns 2,276 shares in the company, valued at $542,348.04. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Michael David Garrison sold 1,715 shares of the company’s stock in a transaction that occurred on Tuesday, April 30th. The shares were sold at an average price of $232.81, for a total value of $399,269.15. Following the completion of the transaction, the executive vice president now owns 5,381 shares in the company, valued at approximately $1,252,750.61. The disclosure for this sale can be found here. 0.31% of the stock is currently owned by corporate insiders.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.